Longeveron (LGVN) Competitors

Longeveron (NASDAQ:LGVN) and XBiotech (NASDAQ:XBIT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, media sentiment, institutional ownership, risk, community ranking and analyst recommendations.

Which has stronger earnings & valuation, LGVN or XBIT?

Longeveron has higher earnings, but lower revenue than XBiotech. XBiotech is trading at a lower price-to-earnings ratio than Longeveron, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Longeveron	$2.39M	9.74	-$21.41M	-$6.28	-0.25
XBiotech	$4.01M	22.20	-$24.56M	-$1.26	-2.32

Is LGVN or XBIT more profitable?

XBiotech has a net margin of 0.00% compared to Longeveron's net margin of -967.49%. XBiotech's return on equity of -15.99% beat Longeveron's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Longeveron	-967.49%	-142.43%	-100.84%
XBiotech	N/A	-15.99%	-14.85%

Does the MarketBeat Community believe in LGVN or XBIT?

XBiotech received 299 more outperform votes than Longeveron when rated by MarketBeat users. However, 94.74% of users gave Longeveron an outperform vote while only 69.98% of users gave XBiotech an outperform vote.

Company	Underperform	Outperform
Longeveron	Outperform Votes 18 94.74%	Underperform Votes 1 5.26%
XBiotech	Outperform Votes 317 69.98%	Underperform Votes 136 30.02%

Does the media refer more to LGVN or XBIT?

In the previous week, Longeveron and Longeveron both had 1 articles in the media. Longeveron's average media sentiment score of 1.87 beat XBiotech's score of 1.49 indicating that Longeveron is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Longeveron	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
XBiotech	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts recommend LGVN or XBIT?

Longeveron currently has a consensus target price of $8.67, suggesting a potential upside of 455.56%. Given Longeveron's stronger consensus rating and higher possible upside, analysts plainly believe Longeveron is more favorable than XBiotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Longeveron	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.25
XBiotech	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Do insiders & institutionals have more ownership in LGVN or XBIT?

10.0% of Longeveron shares are held by institutional investors. Comparatively, 55.7% of XBiotech shares are held by institutional investors. 19.1% of Longeveron shares are held by company insiders. Comparatively, 33.1% of XBiotech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Which has more risk and volatility, LGVN or XBIT?

Longeveron has a beta of 0.39, suggesting that its stock price is 61% less volatile than the S&P 500. Comparatively, XBiotech has a beta of 1.28, suggesting that its stock price is 28% more volatile than the S&P 500.

Summary

XBiotech beats Longeveron on 10 of the 18 factors compared between the two stocks.